Liu Lin, Ma Yongping, Zhou Huicong, Wu Mingjun
Key Laboratory of Biochemistry and Molecular Biology, The Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, China.
Institute of Life Science, Chongqing Medical University, Chongqing 400016, China.
Int J Mol Sci. 2016 Aug 27;17(9):1419. doi: 10.3390/ijms17091419.
The nontoxic heat-labile toxin (LT) B subunit (LTB) was used as mucosal adjuvant experimentally. However, the mechanism of LTB adjuvant was still unclear. The LTB and enterovirus 71 (EV71) VP1 subunit (EVP1) were constructed in pET32 and expressed in E. coli BL21, respectively. The immunogenicity of purified EVP1 and the adjuvanticity of LTB were evaluated via intranasal immunization EVP1 plus LTB in Balb/c mice. In order to elucidate the proteome change triggered by the adjuvant of LTB, the proteomic profiles of LTB, EVP1, and LTB plus EVP1 were quantitatively analyzed by iTRAQ-LC-MS/MS (isobaric tags for relative and absolute quantitation; liquid chromatography-tandem mass spectrometry) in murine macrophage RAW264.7. The proteomic data were analyzed by bioinformatics and validated by western blot analysis. The predicted protein interactions were confirmed using LTB pull-down and the LTB processing pathway was validated by confocal microscopy. The results showed that LTB significantly boosted EVP1 specific systematic and mucosal antibodies. A total of 3666 differential proteins were identified in the three groups. Pathway enrichment of proteomic data predicted that LTB upregulated the specific and dominant MAPK (mitogen-activated protein kinase) signaling pathway and the protein processing in endoplasmic reticulum (PPER) pathway, whereas LTB or EVP1 did not significantly upregulate these two signaling pathways. Confocal microscopy and LTB pull-down assays confirmed that the LTB adjuvant was endocytosed and processed through endocytosis (ENS)-lysosomal-endoplasmic reticulum (ER) system.
无毒热不稳定毒素(LT)B亚基(LTB)被用作实验性黏膜佐剂。然而,LTB佐剂的作用机制仍不清楚。LTB和肠道病毒71型(EV71)VP1亚基(EVP1)分别构建于pET32载体中,并在大肠杆菌BL21中表达。通过对Balb/c小鼠进行鼻内免疫EVP1加LTB,评估纯化的EVP1的免疫原性和LTB的佐剂活性。为了阐明LTB佐剂引发的蛋白质组变化,采用iTRAQ-LC-MS/MS(相对和绝对定量等压标签;液相色谱-串联质谱)对小鼠巨噬细胞RAW264.7中LTB、EVP1以及LTB加EVP1的蛋白质组图谱进行定量分析。蛋白质组学数据通过生物信息学进行分析,并通过蛋白质印迹分析进行验证。使用LTB下拉法确认预测的蛋白质相互作用,并通过共聚焦显微镜验证LTB加工途径。结果表明,LTB显著增强了EVP1特异性的全身和黏膜抗体。三组共鉴定出3666种差异蛋白。蛋白质组学数据的通路富集预测,LTB上调了特定且占主导地位的丝裂原活化蛋白激酶(MAPK)信号通路和内质网中的蛋白质加工(PPER)通路,而LTB或EVP1并未显著上调这两条信号通路。共聚焦显微镜和LTB下拉试验证实,LTB佐剂通过内吞作用(ENS)-溶酶体-内质网(ER)系统被内吞和加工。